Horizon Therapeutics [HZNP] vs Eli Lilly and [LLY] Detailed Stock Comparison

Horizon Therapeutics

NASDAQ
Loading...

Eli Lilly and

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Horizon Therapeutics wins in 8 metrics, Eli Lilly and wins in 9 metrics, with 0 ties. Eli Lilly and appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricHorizon TherapeuticsEli Lilly andBetter
P/E Ratio (TTM)61.8655.25Eli Lilly and
Price-to-Book Ratio5.0141.41Horizon Therapeutics
Debt-to-Equity Ratio0.48217.89Horizon Therapeutics
PEG Ratio-16.290.60Horizon Therapeutics
EV/EBITDA24.0832.04Horizon Therapeutics
Profit Margin (TTM)74.64%25.91%Horizon Therapeutics
Operating Margin (TTM)16.83%45.81%Eli Lilly and
EBITDA Margin (TTM)16.83%45.81%Eli Lilly and
Return on Equity10.28%86.29%Eli Lilly and
Return on Assets (TTM)5.72%16.55%Eli Lilly and
Free Cash Flow (TTM)N/A$414.30MN/A
Dividend YieldN/A0.52%N/A
1-Year Return-6.82%-8.23%Horizon Therapeutics
Price-to-Sales Ratio (TTM)7.3414.20Horizon Therapeutics
Enterprise Value$26.84B$793.87BEli Lilly and
EV/Revenue Ratio7.4014.91Horizon Therapeutics
Gross Profit Margin (TTM)76.72%84.27%Eli Lilly and
Revenue per Share (TTM)$16$59Eli Lilly and
Earnings per Share (Diluted)$2.22$15.27Eli Lilly and
Beta (Stock Volatility)N/A0.46N/A
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Horizon Therapeutics vs Eli Lilly and Stock Performance Analysis

Loading Price Chart...

Horizon Therapeutics
Eli Lilly and
Horizon Therapeutics Stock Overview | Eli Lilly and Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Horizon Therapeutics0.00%0.00%0.00%0.00%0.00%0.00%
Eli Lilly and1.14%4.33%13.95%8.70%13.49%9.93%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Horizon Therapeutics-6.82%74.04%9.84%176.66%176.66%176.66%
Eli Lilly and-8.23%158.11%485.38%949.38%2,165.23%1,525.52%

News Based Sentiment: Horizon Therapeutics vs Eli Lilly and

Horizon Therapeutics

News sentiment data is not available for Horizon Therapeutics at this time.

Eli Lilly and

News based Sentiment: POSITIVE

October was a strong month for Eli Lilly, marked by impressive financial results, significant government contracts, and positive analyst activity. While the withdrawal of the Volenrelaxin trial and insider selling introduce some caution, the overall narrative points to continued growth and a positive outlook for the company, making it a significant month for investors.

View Eli Lilly and News Sentiment Analysis

Performance & Financial Health Analysis: Horizon Therapeutics vs Eli Lilly and

MetricHZNPLLY
Market Information
Market Cap i$26.63B$759.43B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i19,134,2064,624,760
90 Day Avg. Volume i8,460,6953,885,110
Last Close$116.30$855.35
52 Week Range$116.30 - $116.34$623.78 - $937.00
% from 52W High-0.03%-8.71%
All-Time High$39.49 (Jul 20, 2015)$972.53 (Aug 19, 2024)
% from All-Time High194.50%-12.05%
Growth Metrics
Quarterly Revenue Growth0.14%0.38%
Quarterly Earnings GrowthN/A0.91%
Financial Health
Profit Margin (TTM) i0.75%0.26%
Operating Margin (TTM) i0.17%0.46%
Return on Equity (TTM) i0.10%0.86%
Debt to Equity (MRQ) i0.48217.89
Cash & Liquidity
Book Value per Share (MRQ)$23.22$20.38
Cash per Share (MRQ)N/A$3.95
Operating Cash Flow (TTM) i$1.33B$10.94B
Levered Free Cash Flow (TTM) i$1.81B$-2,265,437,440
Dividends
Last 12-Month Dividend Yield iN/A0.52%
Last 12-Month Dividend iN/A$4.10

Valuation & Enterprise Metrics Analysis: Horizon Therapeutics vs Eli Lilly and

MetricHZNPLLY
Price Ratios
P/E Ratio (TTM) i61.8655.25
Forward P/E i20.5537.23
PEG Ratio i-16.290.60
Price to Sales (TTM) i7.3414.20
Price to Book (MRQ) i5.0141.41
Market Capitalization
Market Capitalization i$26.63B$759.43B
Enterprise Value i$26.84B$793.87B
Enterprise Value Metrics
Enterprise to Revenue i7.4014.91
Enterprise to EBITDA i24.0832.04
Risk & Other Metrics
Beta iN/A0.46
Book Value per Share (MRQ) i$23.22$20.38

Financial Statements Comparison: Horizon Therapeutics vs Eli Lilly and

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)HZNPLLY
Revenue/Sales iN/A$15.56B
Cost of Goods Sold iN/A$2.45B
Gross Profit iN/A$13.11B
Research & Development iN/A$3.34B
Operating Income (EBIT) iN/A$7.13B
EBITDA iN/A$7.54B
Pre-Tax Income iN/A$6.78B
Income Tax iN/A$1.12B
Net Income (Profit) iN/A$5.66B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)HZNPLLY
Cash & Equivalents iN/A$3.09B
Total Current Assets iN/A$41.26B
Total Current Liabilities iN/A$30.07B
Long-Term Debt iN/A$34.50B
Total Shareholders Equity iN/A$15.85B
Retained Earnings iN/A$15.10B
Property, Plant & Equipment iN/AN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)HZNPLLY
Operating Cash Flow iN/A$4.88B
Capital Expenditures iN/A$-1.51B
Free Cash Flow iN/A$-1.60B
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A$-1.20B

Short Interest & Institutional Ownership Analysis

MetricHZNPLLY
Shares Short iN/A7.32M
Short Ratio iN/A1.93
Short % of Float iN/A0.01%
Average Daily Volume (10 Day) i19,134,2064,624,760
Average Daily Volume (90 Day) i8,460,6953,885,110
Shares Outstanding i229.00M897.54M
Float Shares iN/A895.44M
% Held by Insiders iN/A0.00%
% Held by Institutions iN/A0.84%

Dividend Analysis & Yield Comparison: Horizon Therapeutics vs Eli Lilly and

MetricHZNPLLY
Last 12-Month Dividend iN/A$4.10
Last 12-Month Dividend Yield iN/A0.52%
3-Year Avg Annual Dividend iN/A$4.02
3-Year Avg Dividend Yield iN/A0.22%
3-Year Total Dividends iN/A$12.05
Ex-Dividend DateN/AFeb 14, 2025